1. France Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Boiron SA

Boiron SA

18.00
EUR
0.00
(0.00%)
520.00MMarket Cap
Mar 24Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
31.81
31.64
32.95
33.34
33.51
33.96
31.81
29.33
25.99
30.72
28.41
28.08
28.86
- -
Basic EPS, GAAP
4.24
4.62
4.01
4.22
4.25
3.23
2.32
1.5
1.63
2.57
2.06
0.65
1.88
- -
Free Cash Flow per Basic Share
4.25
3.79
4.18
4.09
2.79
2.06
0.76
2.72
0.74
2.31
1.58
1.36
1.71
- -
Dividend per Share
0.9
1.21
1.5
1.5
1.6
1.59
1.45
1.05
0.95
0.95
11.46
1.35
1.2
- -
Book Value per Share
20.17
20.36
22.58
25.46
28.08
27.74
28.87
29.07
30.36
32.09
22.67
21.78
22.62
22.62
Tangible Book Value per Share
13.73
13.71
15.89
19
21.63
21.12
22.2
22.24
23.48
24.85
15.77
14.93
15.72
15.72
Basic Weighted Avg Shares
19
19
18
18
18
18
18
18
18
17
17
17
17
17
Sales/Revenue/Turnover
618
610
608
614
618
604
557
514
455
534
493
488
501
- -
Operating Margin (%)
21.92
23.46
21.42
21.07
19.78
16.41
13.2
13.58
8.69
10.6
8.27
7.35
7.26
- -
Depreciation Expense
33
18
29
29
29
34
38
69
18
17
26
42
19
- -
Net Income, GAAP
82
89
74
78
78
57
41
26
29
45
36
11
33
- -
Effective Tax Rate (%)
37.24
36.98
40.13
38.76
36.49
44.75
36.97
29.58
38.07
25.2
27.56
22.24
23.84
- -
Profit Margin (%)
13.34
14.6
12.16
12.65
12.67
9.51
7.29
5.1
6.27
8.36
7.26
2.33
6.51
- -
Working Capital
187
193
227
276
306
254
276
265
294
325
160
169
161
161
LT Debt
3
4
5
5
5
4
10
9
8
17
7
10
19
19
Total Equity
392
380
416
470
517
486
505
509
532
557
392
378
393
393
Return on Invested Capital (%)
22.67
22.7
18.49
17.52
15.68
11.43
8.33
5.16
5.44
8.44
6.21
3.06
8.12
- -
Return on Capital (%)
22.71
22.83
18.33
17.36
15.56
11.23
8.1
5.09
5.4
8.1
7.84
3.08
8.19
- -
Return on Common Equity (%)
22.96
23.09
18.58
17.56
15.85
11.45
8.2
5.17
5.49
8.2
7.53
2.94
8.47
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
5
4
13
LT Borrowings
4
7
4
LT Finance Leases
7
7
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
461
389
520

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
281
267
294
Cash, Cash Equivalents & STI
65
62
79
Accounts Receivable, Net
90
77
94
Inventories
101
104
99
Total Current Liabilities
112
112
132
Payables & Accruals
- -
- -
- -
ST Debt
5
4
13
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.17%
-4.01%
3.86%
Free Cash Flow
24.87%
23.67%
25.9%
Net Income, GAAP
7.97%
33.04%
187.96%
Sales/Revenue/Turnover
-1.62%
-0.01%
2.78%
Total Cash Common Dividend
96.08%
199.22%
-11.11%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
493
2024
- -
- -
488
2025
- -
- -
501

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2.06
2024
- -
- -
0.65
2025
- -
- -
1.88

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
11.46
2024
- -
- -
1.35
2025
- -
- -
1.2

Company Description

Company Profile APIChatGPT
CEO
Pascal Houdayer
Full Time Employees
2,634
Sector
Health technology
Industry
Pharmaceuticals: other
Address
2, avenue de l’Ouest Lyonnais Messimy AR France 69510
IPO Date
Mar 25, 1991
Website
boironfinance.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Boiron SA manufactures and markets homeopathic medicines worldwide. The company produces non-proprietary homeopathic medicines without specific therapeutic indications and proprietary specialties including Oscillococcinum for flu-like symptoms, Stodal and Stodaline cough syrups, Arnigel arnica gel, Camilia oral solution for teething, Sedatif PC tablets for sleep and anxiety, Coryzalia pellets for colds, Homeoptic eye drops, Homeovox lozenges for hoarseness, as well as additional products such as Acidil for heartburn, GasCalm for bloating, Euphralia eye drops, and Homeodent oral care items; it also offers cosmetics and natural health solutions. Boiron operates through geographic segments comprising France, other European countries, North America, and additional international markets, with over 50% of sales generated outside France via 23 subsidiaries and 30 distributors. Founded in 1932 by pharmacists Jean and Henri Boiron and headquartered in Messimy, France, the company employs approximately 2,800 people and maintains an integrated value chain from research and manufacturing to distribution. In 2023, EW Healthcare Partners acquired a 25% minority stake in Boiron Developpement, which holds the Boiron family's 70% interest and the employee fund's 5% stake in a transaction valuing the group at around EUR 875 million enterprise value, enabling a planned tender offer and supporting expansion into new healthcare verticals particularly in the U.S.; the company reported H1 2025 revenue of EUR 245.6 million, up 7.6% year-over-year, with net income rising 241% to EUR 11.4 million amid strong North American growth and improved margins.